Ditchcarbon
  • Contact
  1. Organizations
  2. Hikma Pharmaceuticals
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 5 days ago

Hikma Pharmaceuticals

Company website

Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.

DitchCarbon Score

How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

72

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Hikma Pharmaceuticals's score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Let us know if this data was useful to you

Hikma Pharmaceuticals's reported carbon emissions

In 2024, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 120,273,000 kg CO2e for Scope 1 and 2 combined, with Scope 1 emissions at about 38,469,000 kg CO2e and Scope 2 emissions at approximately 85,682,000 kg CO2e (market-based). The company also disclosed Scope 3 emissions of around 42,606,000 kg CO2e, which includes significant contributions from purchased goods and services (approximately 681,235,000 kg CO2e) and use of sold products (about 42,089,000 kg CO2e). Hikma has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment reflects their ongoing efforts to enhance sustainability and reduce their carbon footprint. Notably, since 2017, the company has achieved a 4% reduction in reported GHG emissions from direct fuel usage and electricity consumption. The company aims to achieve net zero emissions by 2050, demonstrating a long-term commitment to climate action. These targets and achievements are part of Hikma's broader strategy to address climate change and contribute to a sustainable future.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201320142015201620172018201920202021202220232024
Scope 1
16,817,000
-
-
00,000,000
00,000,000
-
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
49,779,000
00,000,000
00,000,000
00,000,000
00,000,000
-
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
-
-
-
000,000,000
000,000,000
000,000,000
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Hikma Pharmaceuticals's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Hikma Pharmaceuticals is in GB, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Hikma Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Bausch & Lomb Incorporated

US
•
Pharmaceutical Preparation Manufacturing
Updated 29 days ago

Indivior

US
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated about 13 hours ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 7 hours ago

Boehringer Ingelheim Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251028.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy